Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2401 - 2425 of 15094 in total

Pimavanserin

Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT2A and HT2C receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the...
Approved
Investigational
Matched Description: … thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT2A and ... [A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia ... [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions …

Chlorpromazine

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Approved
Investigational
Vet approved
Matched Description: … Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the …

Brentuximab vedotin

Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the...
Approved
Investigational
Matched Description: … Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. ... Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously ... was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Paritaprevir

Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Description: … : Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). ... FDA- and Health Canada-approved product Technivie. ... mature virus: NS3, NS4A, NS4B, NS5A, and NS5B [A19643]. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... ombitasvir, paritaprevir and ritonavir ... dasabuvir, ombitasvir, paritaprevir and ritonavir …

Sulfabenzamide

Sulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.
Approved
Matched Description: … Sulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide …

Potassium cation

Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium...
Approved
Investigational
Matched Description: … The balance between potassium and sodium is maintained by ion pumps in the cell membrane. ... differences of these charged particles causes a difference in electric potential between the inside and ... Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of …

Amodiaquine

A 4-aminoquinoquinoline compound with anti-inflammatory properties.
Approved
Investigational
Matched Categories: … artesunate and amodiaquine ... Antiparasitic Products, Insecticides and Repellents …

Lapatinib

Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a...
Approved
Investigational
Matched Description: … anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and ... Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Streptomycin

Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.[A233325,A232294] Although streptomycin was the first antibiotic...
Approved
Vet approved
Matched Description: … Medicine for their discovery of streptomycin and its antibacterial activity. ... [A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in ... Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and …
Matched Categories: … Alimentary Tract and Metabolism ... streptomycin and isoniazid …

Aducanumab

Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab.[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a...
Approved
Investigational
Matched Description: … that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and ... ] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and ... [A235668] Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Edaravone

Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties. It has three tautomers. Edaravone works to scavenge reactive oxygen species, which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia.[A19140,L44007,A254257] The intravenous formulation of edaravone was first approved in Japan in...
Approved
Investigational
Matched Description: … Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties. ... , which have been implicated in neurological disorders, such as amyotrophic lateral sclerosis (ALS) and ... [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and …

Carbamazepine

Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1....
Approved
Investigational
Matched Description: … and to treat pain resulting from trigeminal neuralgia. ... Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures …

Fosnetupitant

In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Description: … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation ... of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) ... as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting …
Matched Categories: … Netupitant and prodrug …

Cyclophosphamide

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects,...
Approved
Investigational
Matched Description: … It has been used in the treatment of lymphoma and leukemia. ... Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. ... Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Mepolizumab

Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically defined as absolute eosinophil levels of 1500/mm3 or more) is associated with a spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The pathogenesis of eosinophilia is complex, but IL-5 is recognized as...
Approved
Investigational
Matched Description: … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote ... Eosinophils are involved in inflammatory immune responses, and prolonged hypereosinophilia (typically ... spectrum of diseases, including severe asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Evinacumab

Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in...
Approved
Investigational
Matched Description: … [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively ... provides a unique and synergistic therapeutic option in the treatment of HoFH. ... a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Ergoloid mesylate

Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine. The derivatives of this fungus are identified to be about 350 different substances from which the components...
Approved
Matched Description: … [A32912] All these components are produced by the fungus _Claviceps purpurea_ and are all derivatives ... equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and ... [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November …
Matched Categories: … Ergot Alkaloids and Derivatives …

Flucytosine

A fluorinated cytosine analog that is used as an antifungal agent.
Approved
Investigational
Matched Categories: … Fluorouracil and prodrugs …

Thiabendazole

2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)
Approved
Vet approved
Matched Description: … It has CNS side effects and hepatototoxic potential. ... (From Smith and Reynard, Textbook of Pharmacology, 1992, p919) ... It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. …
Matched Categories: … Imidazole and Triazole Derivatives ... Antiparasitic Products, Insecticides and Repellents …

Gimeracil

Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the main active componets within chemotherapy regimens. Approved by the European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with DB03209 and DB09256 within the commercially available product "Teysuno". The main active...
Approved
Matched Description: … Gimeracil is an adjunct to antineoplastic therapy, used to increase the concentration and effect of the ... European Medicines Agency (EMA) in March 2011, Gimeracil is available in combination with [DB03209] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …

Ropeginterferon alfa-2b

Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia.[A242000, A242005] Interferon alfa-2b has been used for decades to treat PV but requires frequent dosing...
Approved
Investigational
Matched Description: … and clinical trials. ... platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term ... propensity for myelofibrosis and leukemia. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Elexacaftor

Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaftor as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure...
Approved
Investigational
Matched Description: … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as ... Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and ... to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and …
Matched Categories: … ivacaftor, tezacaftor and elexacaftor …

Erdafitinib

In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing...
Approved
Investigational
Matched Description: … for patients with metastatic bladder cancer, which demonstrates the development of more personalized and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Lumateperone

Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the...
Approved
Investigational
Matched Description: … Schizophrenia is a complex mental illness and impacts approximately 1% of the population. ... [L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine ... ] available for clinical use, they are generally accompanied by significant metabolic and/or neurological …

Aprocitentan

Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker,...
Approved
Investigational
Matched Description: … [A263386] and have traditionally had limited additional treatment options. ... Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension ... pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker, and …
Displaying drugs 2401 - 2425 of 15094 in total